Increases Full-Year 2023 Earnings Guidance
|
Quarter ended |
||
|
|
||
|
2023 |
|
2022 |
|
|
|
|
(In millions, except per-share results) |
|||
Premium Revenue |
|
|
|
Total Revenue |
|
|
|
|
|
|
|
GAAP: |
|
|
|
Net Income |
|
|
|
EPS – Diluted |
|
|
|
Medical Care Ratio (MCR) |
87.1% |
|
87.1% |
G&A Ratio |
7.2% |
|
7.4% |
After-tax Margin |
3.9% |
|
3.3% |
|
|
|
|
Adjusted: |
|
|
|
Net Income |
|
|
|
EPS – Diluted |
|
|
|
G&A Ratio |
7.2% |
|
7.1% |
After-tax Margin |
4.1% |
|
3.7% |
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release. |
Quarter Highlights
-
As of
March 31, 2023 , the Company served approximately 5.3 million members, an increase of 4% compared toMarch 31, 2022 . -
Premium revenue was approximately
$7.9 billion for the first quarter of 2023, an increase of 5% compared to the first quarter of 2022. -
GAAP net income was
$5.52 per diluted share for the first quarter of 2023, an increase of 26% compared to the first quarter of 2022. -
Adjusted net income was
$5.81 per diluted share for the first quarter of 2023, an increase of 19% compared to the first quarter of 2022. -
The Company increased its full year 2023 adjusted earnings guidance to at least
$20.25 per diluted share, compared to its previous guidance of at least$19.75 per diluted share.
“We are very pleased with our first quarter results and increased 2023 earnings guidance,” said
Premium Revenue
Premium revenue was
Net Income
GAAP net income for the first quarter of 2023 was
Medical Care Ratio
- The consolidated MCR for the first quarter of 2023 was 87.1%, reflecting continued strong medical cost management.
- The Medicaid MCR for the first quarter of 2023 was 88.4%, in line with the Company’s expectation and long-term target range.
- The Medicare MCR for the first quarter of 2023 was 88.0%, in line with the Company’s expectation and long-term target range.
- The Marketplace MCR for the first quarter of 2023 was 68.6%, reflecting the Company’s pricing strategy and seasonality.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the first quarter of 2023 were 7.2%, reflecting new business implementation spending ahead of new contract wins, incepting in
Balance Sheet
Cash and investments at the parent company were
Days in claims payable at
Cash Flow
Operating cash flow for the first quarter of 2023 was
2023 Guidance
The Company increased its full year 2023 adjusted earnings per share guidance to at least
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s first quarter 2023 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2023 guidance, including the Company’s plans and expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of
|
|||||
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
|||||
|
Three Months Ended |
||||
|
|
||||
|
2023 |
|
2022 |
||
|
|
|
|
||
|
(In millions, except per-share amounts) |
||||
Revenue: |
|
|
|
||
Premium revenue |
$ |
7,885 |
|
$ |
7,531 |
Premium tax revenue |
|
172 |
|
|
208 |
Investment income |
|
71 |
|
|
11 |
Other revenue |
|
21 |
|
|
20 |
Total revenue |
|
8,149 |
|
|
7,770 |
Operating expenses: |
|
|
|
||
Medical care costs |
|
6,871 |
|
|
6,563 |
General and administrative expenses |
|
591 |
|
|
571 |
Premium tax expenses |
|
172 |
|
|
208 |
Depreciation and amortization |
|
44 |
|
|
40 |
Other |
|
16 |
|
|
16 |
Total operating expenses |
|
7,694 |
|
|
7,398 |
Operating income |
|
455 |
|
|
372 |
Other expenses, net: |
|
|
|
||
Interest expense |
|
28 |
|
|
28 |
Total other expenses, net |
|
28 |
|
|
28 |
Income before income tax expense |
|
427 |
|
|
344 |
Income tax expense |
|
106 |
|
|
86 |
Net income |
$ |
321 |
|
$ |
258 |
|
|
|
|
||
Net income per share – Diluted |
$ |
5.52 |
|
$ |
4.39 |
|
|
|
|
||
Diluted weighted average shares outstanding |
|
58.0 |
|
|
58.7 |
|
|||||||
CONSOLIDATED BALANCE SHEETS |
|||||||
|
|
|
|
||||
|
2023 |
|
2022 |
||||
|
Unaudited |
|
|
||||
|
(Dollars in millions, except per-share amounts) |
||||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
4,554 |
|
|
$ |
4,006 |
|
Investments |
|
3,810 |
|
|
|
3,499 |
|
Receivables |
|
2,536 |
|
|
|
2,302 |
|
Prepaid expenses and other current assets |
|
259 |
|
|
|
277 |
|
Total current assets |
|
11,159 |
|
|
|
10,084 |
|
Property, equipment, and capitalized software, net |
|
274 |
|
|
|
259 |
|
|
|
1,369 |
|
|
|
1,390 |
|
Restricted investments |
|
242 |
|
|
|
238 |
|
Deferred income taxes |
|
208 |
|
|
|
220 |
|
Other assets |
|
119 |
|
|
|
123 |
|
Total assets |
$ |
13,371 |
|
|
$ |
12,314 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Medical claims and benefits payable |
$ |
3,824 |
|
|
$ |
3,528 |
|
Amounts due government agencies |
|
2,349 |
|
|
|
2,079 |
|
Accounts payable, accrued liabilities and other |
|
787 |
|
|
|
889 |
|
Deferred revenue |
|
654 |
|
|
|
359 |
|
Total current liabilities |
|
7,614 |
|
|
|
6,855 |
|
Long-term debt |
|
2,177 |
|
|
|
2,176 |
|
Finance lease liabilities |
|
204 |
|
|
|
215 |
|
Other long-term liabilities |
|
88 |
|
|
|
104 |
|
Total liabilities |
|
10,083 |
|
|
|
9,350 |
|
Stockholders’ equity: |
|
|
|
||||
Common stock, |
|
— |
|
|
|
— |
|
Preferred stock, |
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
296 |
|
|
|
328 |
|
Accumulated other comprehensive loss |
|
(125 |
) |
|
|
(160 |
) |
Retained earnings |
|
3,117 |
|
|
|
2,796 |
|
Total stockholders’ equity |
|
3,288 |
|
|
|
2,964 |
|
Total liabilities and stockholders’ equity |
$ |
13,371 |
|
|
$ |
12,314 |
|
|
|||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
|
Three Months Ended |
||||||
|
|
||||||
|
2023 |
|
2022 |
||||
|
|
|
|
||||
|
(In millions) |
||||||
Operating activities: |
|
|
|
||||
Net income |
$ |
321 |
|
|
$ |
258 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
44 |
|
|
|
40 |
|
Deferred income taxes |
|
1 |
|
|
|
16 |
|
Share-based compensation |
|
25 |
|
|
|
34 |
|
Other, net |
|
5 |
|
|
|
(8 |
) |
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
|
(234 |
) |
|
|
21 |
|
Prepaid expenses and other current assets |
|
7 |
|
|
|
(32 |
) |
Medical claims and benefits payable |
|
296 |
|
|
|
263 |
|
Amounts due government agencies |
|
270 |
|
|
|
137 |
|
Accounts payable, accrued liabilities and other |
|
(215 |
) |
|
|
(81 |
) |
Deferred revenue |
|
295 |
|
|
|
(352 |
) |
Income taxes |
|
101 |
|
|
|
67 |
|
Net cash provided by operating activities |
|
916 |
|
|
|
363 |
|
Investing activities: |
|
|
|
||||
Purchases of investments |
|
(646 |
) |
|
|
(403 |
) |
Proceeds from sales and maturities of investments |
|
371 |
|
|
|
513 |
|
Purchases of property, equipment, and capitalized software |
|
(32 |
) |
|
|
(23 |
) |
Other, net |
|
5 |
|
|
|
(13 |
) |
Net cash (used in) provided by investing activities |
|
(302 |
) |
|
|
74 |
|
Financing activities: |
|
|
|
||||
Common stock withheld to settle employee tax obligations |
|
(58 |
) |
|
|
(52 |
) |
Contingent consideration liabilities settled |
|
— |
|
|
|
(20 |
) |
Other, net |
|
(7 |
) |
|
|
(5 |
) |
Net cash used in financing activities |
|
(65 |
) |
|
|
(77 |
) |
Net increase in cash, cash equivalents, and restricted cash and cash equivalents |
|
549 |
|
|
|
360 |
|
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
|
4,048 |
|
|
|
4,506 |
|
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
4,597 |
|
|
$ |
4,866 |
|
|
|
|
|
|
||||||
UNAUDITED SEGMENT DATA |
||||||
(Dollars in millions) |
||||||
|
|
|
|
|
|
|
|
|
2023 |
|
2022 |
|
2022 |
Ending Membership by Segment: |
|
|
|
|
|
|
Medicaid |
4,834,000 |
|
4,754,000 |
|
4,566,000 |
|
Medicare |
161,000 |
|
156,000 |
|
148,000 |
|
Marketplace |
271,000 |
|
348,000 |
|
371,000 |
|
Total |
5,266,000 |
|
5,258,000 |
|
5,085,000 |
|
|
|
|
|
|
|
|
|
Three Months Ended |
||||||||||||||||
|
2023 |
|
2022 |
||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
||||||
|
|
|
|
|
|
||||||||||||
Medicaid |
$ |
6,349 |
|
$ |
734 |
|
88.4 |
% |
|
$ |
5,980 |
|
$ |
710 |
|
88.1 |
% |
Medicare |
|
1,046 |
|
|
126 |
|
88.0 |
|
|
|
943 |
|
|
128 |
|
86.5 |
|
Marketplace |
|
490 |
|
|
154 |
|
68.6 |
|
|
|
608 |
|
|
130 |
|
78.6 |
|
Consolidated |
$ |
7,885 |
|
$ |
1,014 |
|
87.1 |
% |
|
$ |
7,531 |
|
$ |
968 |
|
87.1 |
% |
__________________
(1) |
The MCR represents medical costs as a percentage of premium revenue. |
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Three Months Ended |
||||||
|
|
||||||
|
2023 |
|
2022 |
||||
|
|
|
|
||||
|
Unaudited |
||||||
Medical claims and benefits payable, beginning balance |
$ |
3,528 |
|
|
$ |
3,363 |
|
Components of medical care costs related to: |
|
|
|
||||
Current year |
|
7,169 |
|
|
|
6,769 |
|
Prior year |
|
(298 |
) |
|
|
(206 |
) |
Total medical care costs |
|
6,871 |
|
|
|
6,563 |
|
Payments for medical care costs related to: |
|
|
|
||||
Current year |
|
4,487 |
|
|
|
4,197 |
|
Prior year |
|
2,358 |
|
|
|
2,199 |
|
Total paid |
|
6,845 |
|
|
|
6,396 |
|
Acquired balances, net of post-acquisition adjustments |
|
— |
|
|
|
(25 |
) |
Change in non-risk and other provider payables |
|
270 |
|
|
|
96 |
|
Medical claims and benefits payable, ending balance |
$ |
3,824 |
|
|
$ |
3,601 |
|
|
|
|
|
||||
Days in Claims Payable (1) |
|
48 |
|
|
|
51 |
|
__________________
(1) |
The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements. |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
|
Three Months Ended |
||||||||||||||
2023 |
|
2022 |
|||||||||||||
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
||||||||
GAAP Net income |
$ |
321 |
|
|
$ |
5.52 |
|
|
$ |
258 |
|
|
$ |
4.39 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Amortization of intangible assets |
$ |
21 |
|
|
$ |
0.38 |
|
|
$ |
18 |
|
|
$ |
0.30 |
|
Acquisition-related expenses (1) |
|
— |
|
|
|
— |
|
|
|
19 |
|
|
|
0.33 |
|
Other (2) |
|
— |
|
|
|
— |
|
|
|
3 |
|
|
|
0.04 |
|
Subtotal, adjustments |
|
21 |
|
|
|
0.38 |
|
|
|
40 |
|
|
|
0.67 |
|
Income tax effect |
|
(5 |
) |
|
|
(0.09 |
) |
|
|
(10 |
) |
|
|
(0.16 |
) |
Adjustments, net of tax |
|
16 |
|
|
|
0.29 |
|
|
|
30 |
|
|
|
0.51 |
|
Adjusted net income |
$ |
337 |
|
|
$ |
5.81 |
|
|
$ |
288 |
|
|
$ |
4.90 |
|
__________________
(1) |
Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs. |
|
(2) |
The three months ended |
|
|||||||
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED) |
|||||||
2023 GUIDANCE |
|||||||
|
Amount |
|
Per Diluted Share (2) |
||||
GAAP Net income |
$ |
1,105 |
|
|
$ |
19.02 |
|
Adjustments: |
|
|
|
||||
Amortization of intangible assets |
|
90 |
|
|
|
1.55 |
|
Acquisition-related expenses |
|
5 |
|
|
|
0.08 |
|
Subtotal, adjustments |
|
95 |
|
|
|
1.63 |
|
Income tax effect (1) |
|
(23 |
) |
|
|
(0.40 |
) |
Adjustments, net of tax |
|
72 |
|
|
|
1.23 |
|
Adjusted net income |
$ |
1,177 |
|
|
$ |
20.25 |
|
|
|
|
|
__________________
(1) |
Income tax effect calculated at the statutory tax rate of approximately 23.7%. |
|
(2) |
Computations assume approximately 58.1 million diluted weighted average shares outstanding. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005700/en/
Investor Contact:
Media Contact:
Source: